Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma

We previously reported that BV enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009–2012 with BV...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Chen, Robert, Palmer, Joycelynne M., Tsai, Ni-Chun, Thomas, Sandra H., Siddiqi, Tanya, Popplewell, Leslie, Farol, Len, Nademanee, Auayporn, Forman, Stephen J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4194250/
https://ncbi.nlm.nih.gov/pubmed/25008328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.06.037
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia